BioSpace News Archive

Business

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

LAVA Therapeutics N.V. announced recent corporate highlights and financial results for the quarter ended September 30, 2023.

November 16, 2023
·
11 min read
Policy

ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-Sufficiency

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its tenth ADMA BioCenters plasma collection facility located in Laurel, Maryland.

November 16, 2023
·
5 min read
Business

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced the appointment of Thomas Riga as Chief Operating and Commercial Officer.

November 16, 2023
·
3 min read
Deals

Q32 Bio and Homology Medicines Announce Merger Agreement

Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

November 16, 2023
·
17 min read
Job Trends

Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine

AbbVie (NYSE: ABBV) today announced detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome of a migraine attack.

November 16, 2023
·
11 min read
Pharm Country

Avantor® to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Avantor, Inc. announced that President and CEO Michael Stubblefield , will be participating in a fireside chat at the Evercore ISI HealthCONx Conference in Miami, Florida on Tuesday, November 28, at 10:00 a.m. Eastern Standard Time.

November 16, 2023
·
1 min read
Drug Development

Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Alentis Therapeutics announced today that the first patient has been dosed in a Phase 1/2 clinical trial of ALE.C04, a Claudin-1 (CLDN1) targeting investigational antibody for the treatment of CLDN1+ tumors.

November 16, 2023
·
3 min read
Genetown

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

AlloVir, Inc. today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

November 16, 2023
·
1 min read
Biotech Bay

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

Alterity Therapeutics today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, D.C.

November 16, 2023
·
5 min read
Pharm Country

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode: “Quantitative EEG - Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease.”

November 16, 2023
·
6 min read